Tiger Brokers

BUZZ-Unity Biotechnology falls as eye disease treatment fails in mid-stage trial

Reuters
Mar 24
BUZZ-<a href="https://laohu8.com/S/UBX">Unity Biotechnology</a> falls as eye disease treatment fails in mid-stage trial

** Shares of Unity Biotechnology UBX.O fall 35.3% to $1.18

** Drug developer says its treatment for a type of eye disease failed to meet the main goal of a mid-stage trial

** Co was testing the treatment in patients with diabetic macular edema $(DME.AU)$, an eye condition that causes swelling in the retina in those who have poor vision despite prior treatment

** Co says the treatment, UBX1325, did not meet the main goal of statistical non-inferiority to Regeneron's REGN.O Eylea, the standard of care treatment for patients with DME

** Co, however, says UBX1325 showed improvements in clarity of vision of over 5 letters at weeks 24 and 36

** Co anticipates the complete results from the remaining patients in Q2 of 2025

** Stock had fallen 49.4% in 2024

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10